This observational study demonstrates the significance of using the chemotherapy toxicity risk score (CTRS) to determine if an elderly patient can safely tolerate standard-dose combination chemotherapy, or would fare better with a reduced-dose regimen.

The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Cardio-oncology is an emerging interdisciplinary practice poised to address care patients who need concurrent cancer and cardiovascular disease therapies as well as the late effects of cancer and cancer treatments.

Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.